• search hit 1 of 1
Back to Result List

Rare SARS-CoV-2 antibody development in cancer patients

  • SARS-CoV-2 antibody development and immunity will be crucial for the further course of the pandemic. Until now, it has been assumed that patients who are infected with SARS-CoV-2 will develop antibodies as has been the case with other coronaviruses, like MERS-CoV and SARS-CoV. In the present study, we analyzed the development of antibodies in 77 patients with an oncologic diagnosis 26 days after positive RT-qPCR testing for SARS-CoV2. RT-qPCR and anti-SARS-CoV2-antibody methods from BGI (MGIEasy Magnetic Beads Virus DNA/RNA Extraction Kit) and Roche (Elecsys Anti-SARS-CoV-2 immunoassay) were used, respectively, according to the manufacturers’ specifications. Surprisingly, antibody development was detected in only 6 of 77 individuals with a confirmed history of COVID-19. Despite multiple testing, the remaining patients did not show measurable antibody concentrations in subsequent tests. These results undermine the previous hypothesis that SARS-CoV2 infections are regularly associated with antibody development and cast doubt on the provided immunity to COVID-19. Understanding the adaptive and humoral response to SARS-CoV2 will play a key role in vaccine development and gaining further knowledge on the pathogenesis.

Export metadata

Additional Services

Search Google Scholar
Metadaten
Author:Louisa Hempel, Jakob Molnar, Sebastian Robert, Julia Veloso, Zeljka Trepotec, Sofie Englisch, Philip Weinzierl, Cordula Schick, Valeria Milani, Katrin Schweneker, Bastian Fleischmann, Josef Scheiber, Beate Gandorfer, Axel Kleespies, Dirk Hempel, Kristina Riedmann, Armin Piehler
URL:https://doi.org/10.1053/j.seminoncol.2020.12.003
Parent Title (English):Seminars in Oncology
Document Type:Article (peer reviewed)
Language:English
Publication Year:2021
Tag:COVID-19; Cancer; Immunity; SARS-CoV2 antibody development
Volume:48
Issue:2
First Page:160
Last Page:165
Peer reviewed:Ja